Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Status:
Completed
Trial end date:
2018-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effect of bexagliflozin compared to
sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in
subjects with type 2 diabetes mellitus (T2DM).